vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and IPG PHOTONICS CORP (IPGP). Click either name above to swap in a different company.
IPG PHOTONICS CORP is the larger business by last-quarter revenue ($274.5M vs $168.4M, roughly 1.6× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 17.1%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 4.4%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
IPG Photonics Corporation is a manufacturer of fiber lasers. IPG Photonics developed and commercialized optical fiber lasers, which are used in a variety of applications including materials processing, medical applications and telecommunications. IPG has manufacturing facilities in the United States, Germany, Russia and Italy.
ESPR vs IPGP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $274.5M |
| Net Profit | — | $13.3M |
| Gross Margin | — | 36.1% |
| Operating Margin | 50.6% | 1.2% |
| Net Margin | — | 4.8% |
| Revenue YoY | 143.7% | 17.1% |
| Net Profit YoY | — | 69.8% |
| EPS (diluted) | $0.32 | $0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $274.5M | ||
| Q3 25 | $87.3M | $250.8M | ||
| Q2 25 | $82.4M | $250.7M | ||
| Q1 25 | $65.0M | $227.8M | ||
| Q4 24 | $69.1M | $234.3M | ||
| Q3 24 | $51.6M | $233.1M | ||
| Q2 24 | $73.8M | $257.6M | ||
| Q1 24 | $137.7M | $252.0M |
| Q4 25 | — | $13.3M | ||
| Q3 25 | $-31.3M | $7.5M | ||
| Q2 25 | $-12.7M | $6.6M | ||
| Q1 25 | $-40.5M | $3.8M | ||
| Q4 24 | — | $7.8M | ||
| Q3 24 | $-29.5M | $-233.6M | ||
| Q2 24 | $-61.9M | $20.2M | ||
| Q1 24 | $61.0M | $24.1M |
| Q4 25 | — | 36.1% | ||
| Q3 25 | — | 39.5% | ||
| Q2 25 | — | 37.3% | ||
| Q1 25 | — | 39.4% | ||
| Q4 24 | — | 38.6% | ||
| Q3 24 | — | 23.2% | ||
| Q2 24 | — | 37.3% | ||
| Q1 24 | — | 38.7% |
| Q4 25 | 50.6% | 1.2% | ||
| Q3 25 | -11.4% | 3.1% | ||
| Q2 25 | 8.6% | 0.0% | ||
| Q1 25 | -34.0% | 0.8% | ||
| Q4 24 | -6.4% | 6.0% | ||
| Q3 24 | -31.0% | -108.7% | ||
| Q2 24 | 3.5% | 4.7% | ||
| Q1 24 | 52.5% | 7.6% |
| Q4 25 | — | 4.8% | ||
| Q3 25 | -35.9% | 3.0% | ||
| Q2 25 | -15.4% | 2.6% | ||
| Q1 25 | -62.2% | 1.6% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | -57.2% | -100.2% | ||
| Q2 24 | -83.9% | 7.8% | ||
| Q1 24 | 44.3% | 9.6% |
| Q4 25 | $0.32 | $0.30 | ||
| Q3 25 | $-0.16 | $0.18 | ||
| Q2 25 | $-0.06 | $0.16 | ||
| Q1 25 | $-0.21 | $0.09 | ||
| Q4 24 | $-0.14 | $0.27 | ||
| Q3 24 | $-0.15 | $-5.33 | ||
| Q2 24 | $-0.33 | $0.45 | ||
| Q1 24 | $0.34 | $0.52 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $839.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $2.1B |
| Total Assets | $465.9M | $2.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $839.3M | ||
| Q3 25 | $92.4M | $870.4M | ||
| Q2 25 | $86.1M | $899.6M | ||
| Q1 25 | $114.6M | $926.9M | ||
| Q4 24 | $144.8M | $930.2M | ||
| Q3 24 | $144.7M | $1.0B | ||
| Q2 24 | $189.3M | $1.1B | ||
| Q1 24 | $226.6M | $1.1B |
| Q4 25 | $-302.0M | $2.1B | ||
| Q3 25 | $-451.4M | $2.1B | ||
| Q2 25 | $-433.5M | $2.1B | ||
| Q1 25 | $-426.2M | $2.1B | ||
| Q4 24 | $-388.7M | $2.0B | ||
| Q3 24 | $-370.2M | $2.1B | ||
| Q2 24 | $-344.2M | $2.3B | ||
| Q1 24 | $-294.3M | $2.3B |
| Q4 25 | $465.9M | $2.4B | ||
| Q3 25 | $364.0M | $2.4B | ||
| Q2 25 | $347.1M | $2.4B | ||
| Q1 25 | $324.0M | $2.3B | ||
| Q4 24 | $343.8M | $2.3B | ||
| Q3 24 | $314.1M | $2.4B | ||
| Q2 24 | $352.3M | $2.5B | ||
| Q1 24 | $373.1M | $2.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $28.8M |
| Free Cash FlowOCF − Capex | — | $10.9M |
| FCF MarginFCF / Revenue | — | 4.0% |
| Capex IntensityCapex / Revenue | 0.0% | 6.5% |
| Cash ConversionOCF / Net Profit | — | 2.17× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-3.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $28.8M | ||
| Q3 25 | $-4.3M | $35.3M | ||
| Q2 25 | $-31.4M | $-2.2M | ||
| Q1 25 | $-22.6M | $13.4M | ||
| Q4 24 | $-35.0M | $73.8M | ||
| Q3 24 | $-35.3M | $66.1M | ||
| Q2 24 | $-7.2M | $53.5M | ||
| Q1 24 | $53.8M | $54.6M |
| Q4 25 | — | $10.9M | ||
| Q3 25 | — | $14.6M | ||
| Q2 25 | — | $-17.6M | ||
| Q1 25 | — | $-11.4M | ||
| Q4 24 | — | $50.6M | ||
| Q3 24 | $-35.5M | $43.0M | ||
| Q2 24 | $-7.3M | $29.2M | ||
| Q1 24 | $53.8M | $26.5M |
| Q4 25 | — | 4.0% | ||
| Q3 25 | — | 5.8% | ||
| Q2 25 | — | -7.0% | ||
| Q1 25 | — | -5.0% | ||
| Q4 24 | — | 21.6% | ||
| Q3 24 | -68.7% | 18.4% | ||
| Q2 24 | -9.9% | 11.3% | ||
| Q1 24 | 39.0% | 10.5% |
| Q4 25 | 0.0% | 6.5% | ||
| Q3 25 | 0.0% | 8.3% | ||
| Q2 25 | 0.0% | 6.1% | ||
| Q1 25 | 0.0% | 10.9% | ||
| Q4 24 | 0.0% | 9.9% | ||
| Q3 24 | 0.3% | 9.9% | ||
| Q2 24 | 0.1% | 9.4% | ||
| Q1 24 | 0.1% | 11.1% |
| Q4 25 | — | 2.17× | ||
| Q3 25 | — | 4.73× | ||
| Q2 25 | — | -0.34× | ||
| Q1 25 | — | 3.58× | ||
| Q4 24 | — | 9.44× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.65× | ||
| Q1 24 | 0.88× | 2.27× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
IPGP
| Materials Processing | $232.8M | 85% |
| Laser And Non Laser Systems | $38.8M | 14% |
| Transferred Over Time | $5.3M | 2% |
